Cargando…

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting

PURPOSE: The purpose of this study was to identify the excision repair cross-complementation group 1 (ERCC1) as a predictive marker for FOLFOX adjuvant chemotherapy in stages II and III colon cancer patients. METHODS: A total of 166 high risk stages II and III colon cancer patients were retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Chee Young, Seo, Sang Hyuk, An, Min Sung, Kim, Kwang Hee, Bae, Ki Beom, Hwang, Jin Won, Kim, Ji Hyun, Kim, Bo Mi, Kang, Mi Seon, Oh, Min Kyung, Hong, Kwan Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Coloproctology 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496459/ https://www.ncbi.nlm.nih.gov/pubmed/26161376 http://dx.doi.org/10.3393/ac.2015.31.3.92

Ejemplares similares

T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy
por: An, Min Sung, et al.
Publicado: (2015)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
por: Kwon, Yujin, et al.
Publicado: (2017)

Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer
por: Park, Dawon, et al.
Publicado: (2018)

Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial
por: Lee, Jii Bum, et al.
Publicado: (2020)

Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy
por: Lee, D-W, et al.
Publicado: (2013)

Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX-4 chemotherapy
por: Han, Song-Hee, et al.
Publicado: (2019)

Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX
por: Kim, Mi-Jung, et al.
Publicado: (2016)

Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy
por: Lee, Suee, et al.
Publicado: (2013)

Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients
por: Lee, Dae-Won, et al.
Publicado: (2015)

Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer
por: Nguyen, T. Quang, et al.
Publicado: (2019)

Association Between a Close Distal Resection Margin and Recurrence After a Sphincter-Saving Resection for T3 Mid- or Low-Rectal Cancer Without Radiotherapy
por: Han, Jae Woong, et al.
Publicado: (2013)

Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer
por: Jeon, Eun Kyoung, et al.
Publicado: (2011)

Changes in Body Composition during Adjuvant FOLFOX Chemotherapy and Overall Survival in Non-Metastatic Colon Cancer
por: Chung, Eric, et al.
Publicado: (2019)

Effect of Adjuvant Chemotherapy on Stage II Colon Cancer: Analysis of Korean National Data
por: Kim, Min Ki, et al.
Publicado: (2018)

Comparison between adjuvant chemotherapy and adjuvant radiotherapy/chemoradiotherapy after radical surgery in patients with cervical cancer: a meta-analysis
por: Lee, Kwang-Beom, et al.
Publicado: (2018)

Alternative Therapy and Abnormal Liver Function During Adjuvant Chemotherapy in Breast Cancer Patients
por: Ahn, Jin-Hee, et al.
Publicado: (2004)

Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian Cancer
por: Lee, Hee Jun, et al.
Publicado: (2013)

ERCC overexpression associated with a poor response of cT4b colorectal cancer with FOLFOX-based neoadjuvant concurrent chemoradiation
por: Huang, Ming-Yii, et al.
Publicado: (2020)

ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy
por: Sun, Jong-Mu, et al.
Publicado: (2012)

Nucleotide Excision Repair Gene ERCC2 and ERCC5 Variants Increase Risk of Uterine Cervical Cancer
por: Joo, Jungnam, et al.
Publicado: (2016)

Relationship between 15-hydroxyprostaglandin dehydrogenase and gastric adenocarcinoma
por: Kang, Jae Hyun, et al.
Publicado: (2014)

Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker
por: Keam, Bhumsuk, et al.
Publicado: (2008)

Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX
por: Lee, Dae-Won, et al.
Publicado: (2015)

Oncologic outcomes of adjuvant chemotherapy alone after radical surgery for stage IB–IIA cervical cancer patients
por: Lee, Kwang-Beom, et al.
Publicado: (2018)

ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
por: Baek, Moo-Jun
Publicado: (2015)

Difference in Tumor Area as a Predictor of a Pathological Complete Response for Patients With Locally Advanced Rectal Cancer
por: Song, Ji Hyeong, et al.
Publicado: (2017)

Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer
por: Kim, Hee Seung, et al.
Publicado: (2012)

Effectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II Colon Cancer
por: Jee, Sun Hee, et al.
Publicado: (2011)

ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen
por: Wei, J, et al.
Publicado: (2008)

Effects of Uncertainty, Appraisal of Uncertainty, and Self-Efficacy on the Quality of Life of Elderly Patients with Lung Cancer Receiving Chemotherapy: Based on Mishel’s Theory of Uncertainty
por: Hwang, Min-Kyung, et al.
Publicado: (2023)

Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2005)

Effects of dodecacalcium hepta-aluminate content on the setting time, compressive strength, alkalinity, and cytocompatibility of tricalcium silicate cement
por: Choi, Yoorina, et al.
Publicado: (2019)

The impact of early adjuvant chemotherapy in rectal cancer
por: Noh, Gyoung Tae, et al.
Publicado: (2020)

Impact of adjuvant chemotherapy for gliomatosis cerebri
por: Kong, Doo-Sik, et al.
Publicado: (2010)

ERCC1 and MGMT Methylation as a Predictive Marker of Relapse and FOLFOX Response in Colorectal Cancer Patients from South Tunisia
por: Jamai, Dhouha, et al.
Publicado: (2023)

Hepatitis B Reactivation During Adjuvant Anthracycline-Based Chemotherapy in Patients with Breast Cancer: A Single Institution's Experience
por: Kim, Min Kyoung, et al.
Publicado: (2007)

Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4)
por: Chen, Chin-Fan, et al.
Publicado: (2008)

Optimal Time of Initiating Adjuvant Chemotherapy After Curative Surgery in Colorectal Cancer Patients
por: Kang, Kyu Min, et al.
Publicado: (2013)

Electroacupuncture for chemotherapy-induced peripheral neuropathy: study protocol for a pilot multicentre randomized, patient-assessor-blinded, controlled trial
por: Kim, Joo-Hee, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vk1g2v5f1gcl5ldg25e4rda109